This segment focuses on the research, development, and commercialization of therapies for anemia associated with chronic kidney disease (CKD). The primary focus is on vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. Research and development activities include Phase 3 clinical trials to evaluate the efficacy and safety of vadadustat in both dialysis-dependent and non-dialysis-dependent CKD patients. Technologies used include small molecule drug development and clinical trial management. The therapeutic area is nephrology, specifically targeting the treatment of anemia in CKD patients. The patient impact is significant, as anemia is a common and debilitating complication of CKD, and vadadustat aims to provide an effective oral treatment option. Market positioning involves competing with existing anemia treatments, such as erythropoiesis-stimulating agents (ESAs). Future opportunities include expanding the use of vadadustat and exploring combination therapies. Regulatory and clinical aspects involve obtaining FDA and other regulatory approvals. Partnerships with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation support the development and commercialization of vadadustat in various regions.

This segment focuses on the commercialization of Auryxia (ferric citrate) for the control of serum phosphorus levels in adult patients with DD-CKD on dialysis and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Research and development activities are focused on lifecycle management of Auryxia, including exploring new formulations and indications. The technology used is based on ferric citrate, a phosphate binder and iron replacement therapy. The therapeutic area is nephrology, specifically targeting the management of hyperphosphatemia and iron deficiency in CKD patients. The patient impact is significant, as Auryxia helps manage a common complication of CKD. Market positioning involves competing with other phosphate binders. Future opportunities include expanding the use of Auryxia and exploring combination therapies. Regulatory and clinical aspects involve maintaining FDA approval and ensuring compliance. This segment is a key part of Akebia's commercial operations.